INT278707

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 2.03
Pain Relevance 0.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (CTBP1) oxidoreductase activity (CTBP1) nucleolus (CTBP1)
nucleus (CTBP1) transcription factor binding (CTBP1) cytoplasm (CTBP1)
Anatomy Link Frequency
joint 1
CTBP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 77 96.24 Very High Very High Very High
cytokine 8 67.20 Quite High
Arthritis 2 50.00 Quite Low
methotrexate 14 45.84 Quite Low
Osteoarthritis 32 43.56 Quite Low
Inflammation 71 5.00 Very Low Very Low Very Low
Leflunomide 15 5.00 Very Low Very Low Very Low
corticosteroid 3 5.00 Very Low Very Low Very Low
Neuropathic pain 2 5.00 Very Low Very Low Very Low
alcohol 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 48 99.24 Very High Very High Very High
Skin Cancer 2 97.80 Very High Very High Very High
Rheumatoid Arthritis 122 96.24 Very High Very High Very High
Disease Progression 6 94.42 High High
Disease 31 94.32 High High
Cancer 160 89.88 High High
Lobular Carcinoma 2 66.68 Quite High
Colon Cancer 2 50.72 Quite High
Frailty 34 43.56 Quite Low
Autoimmune Disease 7 17.76 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It included CTBP1, whose decreased expression has been associated with migratory, invasive potential of melanoma cells [53].
Gene_expression (expression) of CTBP1 associated with skin cancer
1) Confidence 0.51 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.69 Pain Relevance 0
However, we did not observe downregulated CTBP1 expression in proportion to the deletion of this region.
Gene_expression (expression) of CTBP1
2) Confidence 0.51 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.66 Pain Relevance 0
Many factors have been reported to predict disease progression, responsiveness to therapy or remission, including antibody levels to citrullinated peptides [37], [38] and citrullinated fibrinogen [39], low baseline serum soluble IL-2 receptor levels [40], early response to DMARD treatment [41], [42], the active joint count [43] or urinary levels of C-terminal crosslinking telopeptide of type 1 (CTX-I) and type II (CTX-II) [44].
Gene_expression (levels) of C-terminal crosslinking telopeptide of type 1 in joint associated with disease progression
3) Confidence 0.08 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2724743 Disease Relevance 0.69 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox